Do We Still Need Randomized Controlled Trials to Support Use of New Methods of Breast Cancer Screening?

Area of Science:

• Medical Imaging
• Health Technology Assessment
• Radiology

Background:

• Randomized controlled trials (RCTs) are crucial for validating medical interventions, including screening mammography.
• The pace of innovation in breast radiology and artificial intelligence outstrips the timeline for conducting traditional RCTs.
• Regulatory approval and market forces can lead to widespread adoption of technologies before robust efficacy data is available.

Purpose of the Study:

• To explore the challenges of using RCTs for evaluating rapidly evolving breast imaging technologies.
• To identify alternative data sources and professional initiatives for evidence-based technology integration.
• To propose a middle ground between RCT data and clinical decision-making.

Main Methods:

• Literature review of RCT benefits and drawbacks.
• Analysis of factors influencing technology adoption (regulatory approval, marketing, patient demand).
• Exploration of professional initiatives like method of detection tracking.

Main Results:

• RCTs are time-consuming and expensive, posing a barrier to evaluating fast-developing technologies.
• A gap exists between RCT evidence and real-world clinical application.
• Professional initiatives may offer faster, reasoned evaluation methods.

Conclusions:

• The breast imaging community needs to adapt evaluation methods for new technologies.
• Exploring alternative data and professional initiatives can facilitate quicker, evidence-based integration.
• Finding a balance is essential for timely patient care and technological advancement.